Cognitive enhancement as a treatment for drug addictions

Neuropharmacology

Volumn 64, Issue , 2013, Pages 452-463

  Sofuoglu, Mehmet ^a   Devito, Elise E ^a   Waters, Andrew J ^b   Carroll, Kathleen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Addiction; Cognition; Cognitive enhancers; Pharmacotherapy

Indexed keywords

ATOMOXETINE; CYCLOSERINE; GALANTAMINE; GUANFACINE; MEMANTINE; METHYLPHENIDATE; MINOCYCLINE; MODAFINIL; NOOTROPIC AGENT; PLACEBO; VARENICLINE;

ACNE; ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; CANNABIS ADDICTION; CIGARETTE SMOKING; COCAINE DEPENDENCE; COGNITION; COGNITIVE BIAS MODIFICATION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXECUTIVE FUNCTION; FUNCTIONAL NEUROIMAGING; HUMAN; HYPERTENSION; MEMORY DISORDER; MENTAL DISEASE; METHAMPHETAMINE DEPENDENCE; NARCOLEPSY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHOBIA; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RESPONSE INHIBITION; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE; WORKING MEMORY; ADDICTION; ANIMAL; DRUG EFFECT; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY;

ANIMALS; BEHAVIOR THERAPY; COGNITION; COGNITION DISORDERS; COMBINED MODALITY THERAPY; EXECUTIVE FUNCTION; HUMANS; NOOTROPIC AGENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84866428257     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.06.021     Document Type: Review

References (170)

1. K. Abernathy, L.J. Chandler, and J.J. Woodward Alcohol and the prefrontal cortex Int. Rev. Neurobiol. 91 2010 289 320
2. E. Aharonovich, E. Nunes, and D. Hasin Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment Drug Alcohol Depend. 71 2003 207 211
3. E. Aharonovich, D.S. Hasin, A.C. Brooks, X. Liu, A. Bisaga, and E.V. Nunes Cognitive deficits predict low treatment retention in cocaine dependent patients Drug Alcohol Depend. 81 2006 313 322
4. E. Aharonovich, A.C. Brooks, E.V. Nunes, and D.S. Hasin Cognitive deficits in marijuana users: effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome Drug Alcohol Depend. 95 2008 279 283
5. A.F. Arnsten Catecholamine influences on dorsolateral prefrontal cortical networks Biol. Psychiatry 69 2011 e89 99
6. Aston-Jones, G.; Gold, J.I.; C. O. N. B. P. A.; Pmid, 2009. How we say no: norepinephrine, inferior frontal gyrus, and response inhibition. Biol. Psychiatry 65, 548-549.
7. A. Bari, A.C. Mar, D.E. Theobald, S.A. Elands, K.C. Oganya, D.M. Eagle, and T.W. Robbins Prefrontal and monoaminergic contributions to stop-signal task performance in rats J. Neurosci. 31 2011 9254 9263
8. M.D. Bell, G.J. Bryson, T.C. Greig, J.M. Fiszdon, and B.E. Wexler Neurocognitive enhancement therapy with work therapy: productivity outcomes at 6- and 12-month follow-ups J. Rehabil. Res. Dev. 42 2005 829 838
9. W.K. Bickel, R. Yi, R.D. Landes, P.F. Hill, and C. Baxter Remember the future: working memory training decreases delay discounting among stimulant addicts Biol. Psychiatry 69 2011 260 265
10. A. Bisaga, E. Aharonovich, W.Y. Cheng, F.R. Levin, J.J. Mariani, W.N. Raby, and E.V. Nunes A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period Drug Alcohol Depend. 111 2010 97 104
11. K.I. Bolla, K. Brown, D. Eldreth, K. Tate, J.L. Cadet, H.G. Pope Jr.; D. Yurgelun-Todd, P.A. Fried, B. Watkinson, R. Gray, K.L. Medina, K.L. Hanson, A.D. Schweinsburg, M. Cohen-Zion, B.J. Nagel, and S.F. Tapert Dose-related neurocognitive effects of marijuana use Neurology 59 2002 1337 1343
12. K. Bolla, M. Ernst, K. Kiehl, M. Mouratidis, D. Eldreth, C. Contoreggi, J. Matochik, V. Kurian, J. Cadet, A. Kimes, F. Funderburk, and E. London Prefrontal cortical dysfunction in abstinent cocaine abusers J. Neuropsychiatry Clin. Neurosci. 16 2004 456 464
13. K.T. Brady, K.M. Gray, and B.K. Tolliver Cognitive enhancers in the treatment of substance use disorders: clinical evidence Pharmacol. Biochem. Behav. 99 2011 285 294
14. J.A. Brewer, P.D. Worhunsky, K.M. Carroll, B.J. Rounsaville, and M.N. Potenza Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients Biol. Psychiatry 64 2008 998 1004
15. B.L. Burke, H. Arkowitz, and M. Menchola The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials J. Consult. Clin. Psychol. 71 2003 843 861
16. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27 2002 699 711
17. E. Carboni, G.L. Tanda, R. Frau, and G. Di Chiara Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals J. Neurochem. 55 1990 1067 1070
18. K.M. Carpenter, E. Schreiber, S. Church, and D. McDowell Drug Stroop performance: relationships with primary substance of use and treatment outcome in a drug-dependent outpatient sample Addict. Behav. 31 2006 174 181
19. K.M. Carroll Combined treatments for substance dependence M.T. Sammons, N.B. Schmidt, Combined Treatments for Mental Disorders: Pharmacological and Psychotherapeutic Strategies for Intervention 2001 APA Press Washington, DC 215 238
20. K.M. Carroll, and L.S. Onken Behavioral therapies for drug abuse Am. J. Psychiatry 162 2005 1452 1460
21. K.M. Carroll, B.J. Rounsaville, L.T. Gordon, C. Nich, P. Jatlow, R.M. Bisighini, and F.H. Gawin Psychotherapy and pharmacotherapy for ambulatory cocaine abusers Arch. Gen. Psychiatry 51 1994 177 187
22. K.M. Carroll, S.A. Ball, S. Martino, C. Nich, T.A. Babuscio, K.F. Nuro, M.A. Gordon, G.A. Portnoy, and B.J. Rounsaville Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT Am. J. Psychiatry 165 2008 881 888
23. K.M. Carroll, B.D. Kiluk, C. Nich, T.A. Babuscio, J.A. Brewer, M.N. Potenza, S.A. Ball, S. Martino, B.J. Rounsaville, and C.W. Lejuez Cognitive function and treatment response in a randomized clinical trial of computer-based training in cognitive-behavioral therapy Subst. Use Misuse 46 2011 23 34
24. T.D. Challman, and J.J. Lipsky Methylphenidate: its pharmacology and uses. Mayo Clinic proceedings Mayo Clinic 75 2000 711 721
25. S.R. Chamberlain, U. Muller, A.D. Blackwell, L. Clark, T.W. Robbins, and B.J. Sahakian Neurochemical modulation of response inhibition and probabilistic learning in humans Science (New York, N.Y 311 2006 861 863
26. S.R. Chamberlain, N. Del Campo, J. Dowson, U. Muller, L. Clark, T.W. Robbins, and B.J. Sahakian Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder Biol. Psychiatry 62 2007 977 984
27. C.D. Chambers, H. Garavan, and M.A. Bellgrove Insights into the neural basis of response inhibition from cognitive and clinical neuroscience Neurosci. Biobehav. Rev. 33 2009 631 646
28. J. Cohen Statistical Power Analysis for the Behavioral Sciences second ed. 1988 L. Erlbaum Associates Hillsdale, N.J. xxi, 567 p.
29. W.M. Cox, L.M. Hogan, M.R. Kristian, and J.H. Race Alcohol attentional bias as a predictor of alcohol abusers' treatment outcome Drug Alcohol Depend. 68 2002 237 243
30. W.M. Cox, E.M. Pothos, and S.G. Hosier Cognitive-motivational predictors of excessive drinkers' success in changing Psychopharmacology (Berl) 192 2007 499 510
31. L. Davis, A. Uezato, J.M. Newell, and E. Frazier Major depression and comorbid substance use disorders Curr. Opin. Psychiatry 21 2008 14 18
32. H. de Wit Impulsivity as a determinant and consequence of drug use: a review of underlying processes Addict. Biol. 14 2009 22 31
33. A.C. Dean, E.D. London, C.A. Sugar, C.M. Kitchen, A.N. Swanson, K.G. Heinzerling, A.D. Kalechstein, and S. Shoptaw Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables Drug Alcohol Depend. 105 2009 48 55
34. A.C. Dean, R.J. Sevak, J.R. Monterosso, G. Hellemann, C.A. Sugar, and E.D. London Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans J. Stud. Alcohol Drugs 72 2011 943 953
35. B. Dell'Osso, M.C. Palazzo, L. Oldani, and A.C. Altamura The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects CNS Neurosci. Ther. 17 2011 723 732
36. E.E. DeVito, A.D. Blackwell, L. Clark, L. Kent, A.M. Dezsery, D.C. Turner, M.R. Aitken, and B.J. Sahakian Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD) Psychopharmacology (Berl) 202 2009 531 539
37. G.C. Dunbar, F. Inglis, R. Kuchibhatla, T. Sharma, M. Tomlinson, and J. Wamsley Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) J. Psychopharmacol. (Oxford, England) 21 2007 171 178
38. T.C. Durazzo, D.J. Meyerhoff, and S.J. Nixon Chronic cigarette smoking: implications for neurocognition and brain neurobiology Int. J. Environ. Res. Public Health 7 2010 3760 3791
39. T.C. Durazzo, D.J. Meyerhoff, and S.J. Nixon A comprehensive assessment of neurocognition in middle-aged chronic cigarette smokers Drug Alcohol Depend. 122 2012 105 111
40. L. Dutra, G. Stathopoulou, S.L. Basden, T.M. Leyro, M.B. Powers, and M.W. Otto A meta-analytic review of psychosocial interventions for substance use disorders Am. J. Psychiatry 165 2008 179 187
41. D.M. Eagle, A. Bari, and T.W. Robbins The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks Psychopharmacology 199 2008 439 456
42. G. Edwards, and M.M. Gross Alcohol dependence: provisional description of a clinical syndrome Br. Med. J. 1 1976 1058 1061
43. D.A. Eldreth, J.A. Matochik, J.L. Cadet, and K.I. Bolla Abnormal brain activity in prefrontal brain regions in abstinent marijuana users Neuroimage 23 2004 914 920
44. S.M. Evans, F.R. Levin, D.J. Brooks, and F. Garawi A pilot double-blind treatment trial of memantine for alcohol dependence Alcohol Clin. Exp. Res. 31 2007 775 782
45. B.J. Everitt, D.M. Hutcheson, K.D. Ersche, Y. Pelloux, J.W. Dalley, and T.W. Robbins The orbital prefrontal cortex and drug addiction in laboratory animals and humans Ann. N. Y. Acad. Sci. 1121 2007 576 597
46. S.V. Faraone, J. Biederman, T. Spencer, D. Michelson, L. Adler, F. Reimherr, and L. Seidman Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder J. Child. Adolesc. Psychopharmacol. 15 2005 664 670
47. M.J. Fernandez-Serrano, J.C. Perales, L. Moreno-Lopez, M. Perez-Garcia, and A. Verdejo-Garcia Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals Psychopharmacology (Berl) 219 2012 673 683
48. M. Field, and W.M. Cox Attentional bias in addictive behaviors: a review of its development, causes, and consequences Drug Alcohol Depend. 97 2008 1 20
49. M. Field, M.R. Munafo, and I.H. Franken A meta-analytic investigation of the relationship between attentional bias and subjective craving in substance abuse Psychol. Bull. 135 2009 589 607
50. M.T. Fillmore, and C.R. Rush Impaired inhibitory control of behavior in chronic cocaine users Drug Alcohol Depend. 66 3 2002 265 273
51. I.H. Franken Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 563 579
52. I.H. Franken, V.M. Hendriks, C.J. Stam, and W. Van den Brink A role for dopamine in the processing of drug cues in heroin dependent patients Eur. Neuropsychopharmacol. 14 2004 503 508
53. P.A. Fried, B. Watkinson, and R. Gray Neurocognitive consequences of marihuana-a comparison with pre-drug performance Neurotoxicol. Teratol. 27 2005 231 239
54. J.I. Friedman, D.N. Adler, H.D. Temporini, E. Kemether, P.D. Harvey, L. White, M. Parrella, and K.L. Davis Guanfacine treatment of cognitive impairment in schizophrenia Neuropsychopharmacology 25 2001 402 409
55. N.P. Friedman, A. Miyake, S.E. Young, J.C. Defries, R.P. Corley, and J.K. Hewitt Individual differences in executive functions are almost entirely genetic in origin J. Exp. Psychol. Gen. 137 2008 201 225
56. D.G. Ghahremani, G. Tabibnia, J. Monterosso, G. Hellemann, R.A. Poldrack, and E.D. London Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals Neuropsychopharmacology 36 2011 950 959
57. R.Z. Goldstein, and N.D. Volkow Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications Nat. Rev. Neurosci. 12 2011 652 669
58. R.Z. Goldstein, P.A. Woicik, T. Maloney, D. Tomasi, N. Alia-Klein, J. Shan, J. Honorio, D. Samaras, R. Wang, F. Telang, G.J. Wang, and N.D. Volkow Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task Proc. Natl. Acad. Sci. U S A 107 2010 16667 16672
59. I. Grant, R. Gonzalez, C.L. Carey, L. Natarajan, and T. Wolfson Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study J. Int. Neuropsychol. Soc. 9 2003 679 689
60. S. Gregoire, M. Rivalan, C. Le Moine, and F. Dellu-Hagedorn The synergy of working memory and inhibitory control: behavioral, pharmacological and neural functional evidences Neurobiol. Learn. Mem. 97 2012 202 212
61. S.A. Gruber, and D.A. Yurgelun-Todd Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation Brain Res. Cogn. Brain Res. 23 2005 107 118
62. Y. Hakamata, S. Lissek, Y. Bar-Haim, J.C. Britton, N.A. Fox, E. Leibenluft, M. Ernst, and D.S. Pine Attention bias modification treatment: a meta-analysis toward the establishment of novel treatment for anxiety Biol. Psychiatry 68 2010 982 990
63. C.L. Hart, C.B. Marvin, R. Silver, E.E. Smith, and C. I. N. N. A.; Pmid Is cognitive functioning impaired in methamphetamine users? A critical review Official Publication of American College of Neuropsychopharmacology Neuropsychopharmacology 37 2012 586 608
64. K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder Brain Res. Rev. 61 2009 105 123
65. S.H. Heil, H.W. Holmes, W.K. Bickel, S.T. Higgins, G.J. Badger, H.F. Laws, and D.E. Faries Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users Drug Alcohol Depend. 67 2002 149 156
66. K.G. Heinzerling, A.N. Swanson, S. Kim, L. Cederblom, A. Moe, W. Ling, and S. Shoptaw Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence Drug Alcohol Depend. 109 2010 20 29
67. R. Hester, and H. Garavan Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity J. Neurosci. 24 2004 11017 11022
68. R. Hester, N. Lee, A. Pennay, S. Nielsen, and J. Ferris The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence Exp. Clin. Psychopharmacol. 18 2010 489 497
69. J. Hettema, J. Steele, and W.R. Miller Motivational interviewing Annu. Rev. Clin. Psychol. 1 2005 91 111
70. S.T. Higgins, D.D. Delaney, A.J. Budney, W.K. Bickel, J.R. Hughes, F. Foerg, and J.W. Fenwick A behavioral approach to achieving initial cocaine abstinence Am. J. Psychiatry 148 1991 1218 1224
71. K.P. Hill, and M. Sofuoglu Biological treatments for amfetamine dependence: recent progress CNS Drugs 21 2007 851 869
72. G. Jager, R.S. Kahn, W. Van Den Brink, J.M. Van Ree, and N.F. Ramsey Long-term effects of frequent cannabis use on working memory and attention: an fMRI study Psychopharmacology (Berl) 185 2006 358 368
73. P. Jakala, M. Riekkinen, J. Sirvio, E. Koivisto, K. Kejonen, M. Vanhanen, and P. Riekkinen Jr. Guanfacine, but not clonidine, improves planning and working memory performance in humans Neuropsychopharmacology 20 1999 460 470
74. A.C. Janes, D.A. Pizzagalli, S. Richardt, B.F.B. de, S. Chuzi, G. Pachas, M.A. Culhane, A.J. Holmes, M. Fava, A.E. Evins, and M.J. Kaufman Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence Biol. Psychiatry 67 2010 722 729
75. D. Jovanovski, S. Erb, and K.K. Zakzanis Neurocognitive deficits in cocaine users: a quantitative review of the evidence J. Clin. Exp. Neuropsychol. 27 2005 189 204
76. R.M. Kadden, M.D. Litt, N.L. Cooney, E. Kabela, and H. Getter Prospective matching of alcoholic clients to cognitive-behavioral or interactional group therapy J. Stud. Alcohol 62 2001 359 369
77. A.D. Kalechstein, R. De La Garza 2nd, and T.F. Newton Modafinil administration improves working memory in methamphetamine-dependent individuals who demonstrate baseline impairment Am. J. Addict. 19 2010 340 344
78. P. Kempel, K. Lampe, R. Parnefjord, J. Hennig, and H.J. Kunert Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls Neuropsychobiology 48 2003 95 101
79. B.D. Kiluk, C. Nich, T. Babuscio, and K.M. Carroll Quality versus quantity: acquisition of coping skills following computerized cognitive-behavioral therapy for substance use disorders Addiction 105 2010 2120 2127
80. B.D. Kiluk, C. Nich, and K.M. Carroll Relationship of cognitive function and the acquisition of coping skills in computer assisted treatment for substance use disorders Drug Alcohol Depend. 114 2011 169 176
81. R. Kozak, J.P. Bruno, and M. Sarter Augmented prefrontal acetylcholine release during challenged attentional performance Cereb. Cortex 16 2006 9 17
82. R. Kuczenski, and D.S. Segal Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine J. Neurochem. 68 1997 2032 2037
83. F.R. Levin, S.M. Evans, D.J. Brooks, and F. Garawi Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo Drug Alcohol Depend. 87 2007 20 29
84. E.D. Levin, P.J. Bushnell, and A.H. Rezvani Attention-modulating effects of cognitive enhancers Pharmacol. Biochem. Behav. 99 2011 146 154
85. C.S. Li, and R. Sinha Inhibitory control and emotional stress regulation: neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction Neurosci. Biobehav. Rev. 32 2008 581 597
86. C.S. Li, V. Milivojevic, K. Kemp, K. Hong, and R. Sinha Performance monitoring and stop signal inhibition in abstinent patients with cocaine dependence Drug Alcohol Depend. 85 2006 205 212
87. C.S. Li, P.T. Morgan, D. Matuskey, O. Abdelghany, X. Luo, J.L. Chang, B.J. Rounsaville, Y.S. Ding, and R.T. Malison Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients Proc. Natl. Acad. Sci. U S A 107 2010 14455 14459
88. E.D. London, S.L. Simon, S.M. Berman, M.A. Mandelkern, A.M. Lichtman, J. Bramen, A.K. Shinn, K. Miotto, J. Learn, Y. Dong, J.A. Matochik, V. Kurian, T. Newton, R. Woods, R. Rawson, and W. Ling Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers Arch. Gen. Psychiatry 61 2004 73 84
89. J. Loughead, R. Ray, E.P. Wileyto, K. Ruparel, P. Sanborn, S. Siegel, R.C. Gur, and C. Lerman Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers Biol. Psychiatry 67 2010 715 721
90. J.P. Lussier, S.H. Heil, J.A. Mongeon, G.J. Badger, and S.T. Higgins A meta-analysis of voucher-based reinforcement therapy for substance use disorders Addiction 101 2006 192 203
91. B. Lynch Historical review of computer-assisted cognitive retraining J. Head Trauma Rehabil. 17 2002 446 457
92. Marijuana Treatment Project Research Group Brief treatments for cannabis dependence: findings from a randomized multisite trial J. Consult. Clin. Psychol. 72 2004 455 466
93. G.A. Marlatt, and W.H. George Relapse prevention: introduction and overview of the model Br. J. Addict. 79 1984 261 273
94. A.F. Marquand, S. De Simoni, O.G. O'Daly, S.C. Williams, J. Mourao-Miranda, and M.A. Mehta Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers Official Publication of the American College of Neuropsychopharmacology Neuropsychopharmacology 36 2011 1237 1247
95. R.J. McNally Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders Clin. Psychol. Rev. 27 2007 750 759
96. K.L. Medina, K.L. Hanson, A.D. Schweinsburg, M. Cohen-Zion, B.J. Nagel, and S.F. Tapert Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence J. Int. Neuropsychol. Soc. 13 2007 807 820
97. W.R. Miller Motivation for treatment: a review with special emphasis on alcoholism Psychol. Bull. 98 1985 84 107
98. E.K. Miller, and J.D. Cohen An integrative theory of prefrontal cortex function Annu. Rev. Neurosci. 24 2001 167 202
99. W.R. Miller, and P.L. Wilbourne Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders Addiction 97 2002 265 277
100. M.J. Minzenberg, and C.S. Carter Modafinil: a review of neurochemical actions and effects on cognition Neuropsychopharmacology 33 2008 1477 1502
101. R.L. Mitchell, and L.H. Phillips The psychological, neurochemical and functional neuroanatomical mediators of the effects of positive and negative mood on executive functions Neuropsychologia 45 2007 617 629
102. H. Mizoguchi, K. Takuma, A. Fukakusa, Y. Ito, A. Nakatani, D. Ibi, H.C. Kim, and K. Yamada Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice Psychopharmacology 196 2008 233 241
103. J.R. Monterosso, A.R. Aron, X. Cordova, J. Xu, and E.D. London Deficits in response inhibition associated with chronic methamphetamine abuse Drug Alcohol Depend. 79 2005 273 277
104. L.S. Nandam, R. Hester, J. Wagner, T.D. Cummins, K. Garner, A.J. Dean, B.N. Kim, P.J. Nathan, J.B. Mattingley, and M.A. Bellgrove Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability Biol. Psychiatry 69 2011 902 904
105. L.J. Nestor, D.G. Ghahremani, J. Monterosso, and E.D. London Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine- dependent subjects Psychiatry Res. 194 2011 287 295
106. A.C. Nooyens, B.M. van Gelder, and W.M. Verschuren Smoking and cognitive decline among middle-aged men and women: the Doetinchem Cohort Study Am. J. Public Health 98 2008 2244 2250
107. T.E. Nordahl, R. Salo, and M. Leamon Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review J. Neuropsychiatry Clin. Neurosci. 15 2003 317 325
108. O.A. Onur, T.E. Schlaepfer, J. Kukolja, A. Bauer, H. Jeung, A. Patin, D.M. Otte, N.J. Shah, W. Maier, K.M. Kendrick, G.R. Fink, and R. Hurlemann The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans Biol. Psychiatry 67 2010 1205 1211
109. F. Patterson, C. Jepson, A.A. Strasser, J. Loughead, K.A. Perkins, R.C. Gur, J.M. Frey, S. Siegel, and C. Lerman Varenicline improves mood and cognition during smoking abstinence Biol. Psychiatry 65 2009 144 149
110. F. Patterson, C. Jepson, J. Loughead, K. Perkins, A.A. Strasser, S. Siegel, J. Frey, R. Gur, and C. Lerman Working memory deficits predict short-term smoking resumption following brief abstinence Drug Alcohol Depend. 106 2010 61 64
111. R.H. Paul, A.M. Brickman, R.A. Cohen, L.M. Williams, R. Niaura, S. Pogun, C.R. Clark, J. Gunstad, and E. Gordon Cognitive status of young and older cigarette smokers: data from the international brain database J. Clin. Neurosci. 13 2006 457 465
112. N.M. Petry Contingency management treatments Br. J. Psychiatry 189 2006 97 98
113. H.G. Pope Jr.; and D. Yurgelun-Todd The residual cognitive effects of heavy marijuana use in college students JAMA 275 1996 521 527
114. H.G. Pope Jr.; A.J. Gruber, and D. Yurgelun-Todd The residual neuropsychological effects of cannabis: the current status of research Drug Alcohol Depend. 38 1995 25 34
115. H.G. Pope Jr.; A.J. Gruber, J.I. Hudson, G. Cohane, M.A. Huestis, and D. Yurgelun-Todd Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 69 2003 303 310
116. L.J. Porrino, H.R. Smith, M.A. Nader, and T.J. Beveridge The effects of cocaine: a shifting target over the course of addiction Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1593 1600
117. M.I. Posner, and M.K. Rothbart Attention, self-regulation and consciousness Philos. Trans. R. Soc. Lond. Series B, Biol. Sci. 353 1998 1915 1927
118. M.N. Potenza, M. Sofuoglu, K.M. Carroll, and B.J. Rounsaville Neuroscience of behavioral and pharmacological treatments for addictions Neuron 69 2011 695 712
119. J. Powell, L. Dawkins, R. West, and A. Pickering Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors Psychopharmacology (Berl) 212 2010 537 549
120. K.L. Price, S.M. DeSantis, A.N. Simpson, B.K. Tolliver, A.L. McRae-Clark, M.E. Saladin, N.L. Baker, M.T. Wagner, and K.T. Brady The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina Am. J. Addict. 20 2011 447 455
121. B.P. Ramos, and A.F. Arnsten Adrenergic pharmacology and cognition: focus on the prefrontal cortex Pharmacol. Ther. 113 2007 523 536
122. K.J. Ressler, B.O. Rothbaum, L. Tannenbaum, P. Anderson, K. Graap, E. Zimand, L. Hodges, and M. Davis Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear Arch. Gen. Psychiatry 61 2004 1136 1144
123. T.W. Robbins, and A.F. Arnsten The neuropsychopharmacology of fronto-executive function: monoaminergic modulation Annu. Rev. Neurosci. 32 2009 267 287
124. S.E. Rooke, D.W. Hine, and E.B. Thorsteinsson Implicit cognition and substance use: a meta-analysis Addict. Behav. 33 2008 1314 1328
125. M.R. Rueda, M.K. Rothbart, B.D. McCandliss, L. Saccomanno, M.I. Posner, and C. I.; Pmid 2005,Training, maturation, and genetic influences on the development of executive attention Proc. Natl. Acad. Sci. U S A 102 2005 14931 14936
126. F. Ryan Detected, selected, and sometimes neglected: cognitive processing of cues in addiction Exp. Clin. Psychopharmacol. 10 2002 67 76
127. S. Sabia, M. Marmot, C. Dufouil, and A. Singh-Manoux Smoking history and cognitive function in middle age from the Whitehall II study Arch. Intern. Med. 168 2008 1165 1173
128. SAMHSA, 2011. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: National Findings.
129. E.J. Santa Ana, B.J. Rounsaville, T.L. Frankforter, C. Nich, T. Babuscio, J. Poling, K. Gonsai, K.P. Hill, and K.M. Carroll D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation Drug Alcohol Depend. 104 2009 220 227
130. M. Sarter, J.P. Bruno, V. Parikh, V. Martinez, R. Kozak, and J.B. Richards Forebrain dopaminergic-cholinergic interactions, attentional effort, psychostimulant addiction and schizophrenia EXS 98 2006 65 86
131. M. Sarter, V. Parikh, and W.M. Howe nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms Biochem. Pharmacol. 78 2009 658 667
132. M.A. Sayette, J.W. Schooler, and E.D. Reichle Out for a smoke: the impact of cigarette craving on zoning out during reading Psychol. Sci. 21 2010 26 30
133. L. Scahill, P.B. Chappell, Y.S. Kim, R.T. Schultz, L. Katsovich, E. Shepherd, A.F. Arnsten, D.J. Cohen, and J.F. Leckman A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder Am. J. Psychiatry 158 2001 1067 1074
134. B. Schilstrom, V.B. Ivanov, C. Wiker, and T.H. Svensson Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors Neuropsychopharmacology 32 2007 43 53
135. T.M. Schoenmakers, M. de Bruin, I.F. Lux, A.G. Goertz, D.H. Van Kerkhof, and R.W. Wiers Clinical effectiveness of attentional bias modification training in abstinent alcoholic patients Drug Alcohol Depend. 109 2010 30 36
136. J.C. Scott, S.P. Woods, G.E. Matt, R.A. Meyer, R.K. Heaton, J.H. Atkinson, and I. Grant Neurocognitive effects of methamphetamine: a critical review and meta-analysis Neuropsychol. Rev. 17 2007 275 297
137. J. Shearer, S. Darke, C. Rodgers, T. Slade, I. van Beek, J. Lewis, D. Brady, R. McKetin, R.P. Mattick, A. Wodak, and C. I. N. A. F.; Pmid A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence Addiction 104 2009 224 233
138. S.L. Simon, C.P. Domier, T. Sim, K. Richardson, R.A. Rawson, and W. Ling Cognitive performance of current methamphetamine and cocaine abusers J. Addict. Dis. 21 2002 61 74
139. S.L. Simon, A.C. Dean, X. Cordova, J.R. Monterosso, and E.D. London Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence J. Stud. Alcohol Drugs 71 2010 335 344
140. M. Sofuoglu Cognitive enhancement as a pharmacotherapy target for stimulant addiction Addiction 105 2010 38 48
141. M. Sofuoglu, and K.M. Carroll Effects of galantamine on cocaine use in chronic cocaine users Am. J. Addict. 20 2011 302 303
142. M. Sofuoglu, and T.R. Kosten Pharmacologic management of relapse prevention in addictive disorders Psychiatr. Clin. North Am. 27 2004 627 648
143. M. Sofuoglu, and T.R. Kosten Emerging pharmacological strategies in the fight against cocaine addiction Expert Opin. Emerg. Drugs 11 2006 91 98
144. M. Sofuoglu, M. Mooney, T. Kosten, A. Waters, and K. Hashimoto Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans Psychopharmacology 2010
145. M. Sofuoglu, D.E. Sugarman, and K.M. Carroll Cognitive function as an emerging treatment target for marijuana addiction Exp. Clin. Psychopharmacol. 18 2010 109 119
146. M. Sofuoglu, A.J. Waters, J. Poling, and K.M. Carroll Galantamine improves sustained attention in chronic cocaine users Exp. Clin. Psychopharmacol. 19 2011 11 19
147. M. Sofuoglu, A.I. Herman, Y. Li, and A.J. Waters Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report Psychopharmacology (Berl) 2012 [Epub ahead of print] PubMed PMID: 22700039
148. N. Solowij Do cognitive impairments recover following cessation of cannabis use? Life Sci. 56 1995 2119 2126
149. N. Solowij, P.T. Michie, and A.M. Fox Differential impairments of selective attention due to frequency and duration of cannabis use Biol. Psychiatry 37 1995 731 739
150. N. Solowij, R.S. Stephens, R.A. Roffman, T. Babor, R. Kadden, M. Miller, K. Christiansen, B. McRee, J. Vendetti, and Marijuana Treatment Project Research, G. Cognitive functioning of long-term heavy cannabis users seeking treatment.[comment][erratum appears in JAMA2002 Apr 3;287(13):1651] JAMA 287 2002 1123 1131
151. K. Stavro, J. Pelletier, and S. Potvin Widespread and sustained cognitive deficits in alcoholism: a meta-analysis Addict. Biol. 2012
152. C.C. Streeter, D.B. Terhune, T.H. Whitfield, S. Gruber, O. Sarid-Segal, M.M. Silveri, G. Tzilos, M. Afshar, E.D. Rouse, H. Tian, P.F. Renshaw, D.A. Ciraulo, and D.A. Yurgelun-Todd Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals Official Publication of the American College of Neuropsychopharmacology Neuropsychopharmacology 33 2008 827 836
153. C.J. Swanson, K.W. Perry, S. Koch-Krueger, J. Katner, K.A. Svensson, and F.P. Bymaster Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat Neuropharmacology 50 2006 755 760
154. B.E. Swartz, C.R. McDonald, A. Patel, and D. Torgersen The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls Clin. Neuropharmacol. 31 2008 251 260
155. D.C. Turner, A.D. Blackwell, J.H. Dowson, A. McLean, and B.J. Sahakian Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder Psychopharmacology (Berl) 178 2005 286 295
156. T.H. Turner, S. LaRowe, M.D. Horner, J. Herron, and R. Malcolm Measures of cognitive functioning as predictors of treatment outcome for cocaine dependence J. Subst. Abuse Treat. 37 2009 328 334
157. A. Verdejo-Garcia, P. Betanzos-Espinosa, O.M. Lozano, E. Vergara-Moragues, F. Gonzalez-Saiz, F. Fernandez-Calderon, I. Bilbao-Acedos, and M. Perez-Garcia Self-regulation and treatment retention in cocaine dependent individuals: a longitudinal study Drug Alcohol Depend. 122 2012 142 148
158. N.D. Volkow, L. Chang, G.J. Wang, J.S. Fowler, D. Franceschi, M. Sedler, S.J. Gatley, E. Miller, R. Hitzemann, Y.S. Ding, and J. Logan Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence J. Neurosci. 21 2001 9414 9418
159. M. Wagner, S. Schulze-Rauschenbach, N. Petrovsky, J. Brinkmeyer, C. von der Goltz, G. Grunder, K.N. Spreckelmeyer, T. Wienker, A. Diaz-Lacava, A. Mobascher, N. Dahmen, M. Clepce, N. Thuerauf, F. Kiefer, J.W. de Millas, J. Gallinat, and G. Winterer Neurocognitive impairments in non-deprived smokers-results from a population-based multi-center study on smoking-related behavior Addict. Biol. 2012 10.1111/j.1369-1600.2011.00429.x
160. T.L. Wallace, and R.H. Porter Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease Biochem. Pharmacol. 82 2011 891 903
161. A.J. Waters, S. Shiffman, M.A. Sayette, J.A. Paty, C.J. Gwaltney, and M.H. Balabanis Attentional bias predicts outcome in smoking cessation Health Psychol. 22 2003 378 387
162. S. Wee, and W.L. Woolverton Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine Drug Alcohol Depend. 75 2004 271 276
163. B.E. Wexler, M. Anderson, R.K. Fulbright, and J.C. Gore Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises Am. J. Psychiatry 157 2000 1694 1697
164. R.W.H.J. Wiers, and A.W. Stacy Handbook of Implicit Cognition and Addiction 2006 Sage Publications Thousand Oaks
165. R.W. Wiers, M. Rinck, R. Kordts, K. Houben, and F. Strack Retraining automatic action-tendencies to approach alcohol in hazardous drinkers Addiction 105 2010 279 287
166. R.W. Wiers, C. Eberl, M. Rinck, E.S. Becker, and J. Lindenmeyer Retraining automatic action tendencies changes alcoholic patients' approach bias for alcohol and improves treatment outcome Psychol. Sci. 22 2011 490 497
167. S. Wilhelm, U. Buhlmann, D.F. Tolin, S.A. Meunier, G.D. Pearlson, H.E. Reese, P. Cannistraro, M.A. Jenike, and S.L. Rauch Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder Am. J. Psychiatry 165 2008 335 341 quiz 409
168. A. Yakir, A. Rigbi, K. Kanyas, Y. Pollak, G. Kahana, O. Karni, R. Eitan, S. Kertzman, and B. Lerer Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors The Journal of the European College of Neuropsychopharmacology Eur. Neuropsychopharmacol. 17 2007 339 351
169. K.K. Zakzanis Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers Arch. Clin. Neuropsychol. 16 2001 653 667
170. L. Zhang, K. Kitaichi, Y. Fujimoto, H. Nakayama, E. Shimizu, M. Iyo, and K. Hashimoto Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 2006 1381 1393